

Proton Cancer Centers of America, LLC

5242 Seneca Place
Simi Valley, CA 93063
(805) 340-1668

December 10, 2012


PCCA Introduction Letter

Proton Cancer Centers of America, LLC (PCCA) is a consulting/development firm specializing in the development of "Proton Beam Therapy" centers - for the treatment of cancer. PCCA's team consists of some of the proton therapy industry's most experienced individuals in the areas of business development, marketing, clinic operations, and clinical treatment.


Proton Therapy is a highly advanced form of radiation therapy that uses protons, from hydrogen atoms, once they have been stripped of their electrons and are then accelerated in a large particle accelerator, to precisely target cancerous tumors, throughout the body. Proton Therapy is a proven (FDA Cleared and Medicare Reimbursed) therapy and has effectively been used to treat more than 100,000 cancer patients, worldwide, since the mid 1960's. By utilizing this remarkable technology, each center can successfully treat as many as 1,500 cancer patients - annually. Proton Therapy will provide these patients with the highest attainable cure rates (90%) with the least amount of side effects, or complications, compared to surgery, chemotherapy, and conventional radiation therapy alternatives.

The following graphic best illustrates a common challenge in treating patients with traditional x-rays and shows the benefit of proton therapy. This 4-year-old female Medulablastoma patient has a high risk for life threatening side effects with traditional x-ray therapy. The combination of her chemotherapy and radiation would severely harm the normal tissue in the mouth, neck, thorax, abdomen, and pelvis. If she survived the x-ray treatment, then the normal tissue that was irradiated will have a significant chance of malfunction and developing a second new cancer. Fortunately, protons, due to their positive charge, can be precisely controlled to not irradiate her mouth, neck, thorax, abdomen, and pelvis. As a result, she will not require intensive hospital support. In addition, her risk of developing a second new cancer is reduced by 90%.

4- year old child - Craniospinal Irradiation – Comparison



Protons



X-rays - Photons

Because Proton Therapy provides a very specific dose placement compared to conventional radiation therapy, there is less damage to normal tissue (side effects). Because of the reduced side effects, physicians can prescribe higher doses to the tumors, resulting in higher control of localized cancer, before it spreads. Eradicating cancer before it spreads reduces the need to provide patients additional follow-up cancer therapies. Overall, healthcare costs are reduced due to the reduction in treating side effects or reoccurring cancers. Proton Therapy improves a patient's chances of survival, reduces the overall costs of healthcare, while improving each patient's productivity and quality of life.

Currently, due to the very high capital requirements for these types of projects (typically between \$26M – \$200M) there are only ten operational proton facilities in the U.S. and about another twenty five, abroad. Three of the centers are new (The University of Pennsylvania, Central Du Page, and Hampton University) and are currently ramping up their operations. Additionally, several new projects at facilities such as UCSD, Seattle Cancer Care Alliance, and the Mayo Clinic are scheduled to complete construction within the few years.

Over the next 10 years proton therapy will likely develop into being the optimum cancer therapy, as a primary or secondary therapy, for more than 700,000 of the 1.4 M annually diagnosed cancer patients who now receive radiation - in the states. By attaining just a 20% market penetration a requirement for more than 140 proton facilities, operating at capacity, is needed to service this demand.

In order to meet these market demands and speed up the proliferation of the technology, PCCA will consult for some highly respected healthcare systems and development teams throughout the U.S. PCCA will help their clients reduce the learning curve of understanding all of the complexities of developing a proton therapy center. Additionally, if appropriate, PCCA may, through a structured partnership agreement, assist a JV partnership in the role of developer and/or operating manager, which may significantly lessen the funding, ownership, and operating management responsibilities of the healthcare institution for each project. This may allow for quicker movement of the typically bureaucratic nature of the healthcare institutions.

PCCA was originally formed in 2004, through an exclusive joint development partnership with Hitachi Ltd., of Japan, to spearhead joint development efforts. PCCA terminated its exclusive partnership agreement with Hitachi, thereby allowing PCCA the independent freedom to consult and/or develop its partnerships without regard to any specific technology or vendor.

PCCA now intends to enter into new consulting and/or strategic partnership agreements with various major health systems who are interested in developing proton therapy applications.

PCCA Team

Dennis M. Valencia, has held senior level executive positions, since 1986, for various publicly traded and privately held medical device firms. From 2002-2006, he reported to senior management at Hitachi, Ltd., of Japan, under an exclusive global business development agreement, where he was responsible for developing, presenting, advising, and consulting on nearly all aspects of Hitachi's proton therapy initiatives, worldwide. He has played a key role in all of Hitachi's proton project negotiations, including their high-profile Proton Center at MD Anderson, in Houston.

In 2004, Mr. Valencia, at the request of Hitachi's senior management, structured an exclusive development partnership agreement with Hitachi, which resulted in the creation of PCCA. As CEO of PCCA, he led the development efforts on multiple proton center initiatives, including key projects in San Diego and Seattle. In late 2006, due to management changes, within Hitachi, PCCA terminated its exclusive partnership agreement with Hitachi, thereby allowing PCCA the independent freedom to develop its partnerships without regard to any specific technology or vendor.

Prior to Hitachi (1997-2002), Mr. Valencia was Vice President of Business Development for Optivus Technology, Inc., a competitor to Hitachi, in proton therapy, which spun-off of Loma Linda University Medical Center. At Optivus, He was responsible for spearheading the developments of several large-scale proton center initiatives throughout Europe, Asia, and the U.S.; projects such as The University of Pennsylvania, MD Anderson, and the University of Florida, where he played a vital role in securing that projects first \$27M funding commitment. During his tenure at Optivus,

he also played a vital role in developing and implementing key patient marketing initiatives for Loma Linda's Proton Facility.

Prior to Optivus (1986-1994), Mr. Valencia was Vice President of Sales & Marketing for International Remote Imaging Systems, a publicly traded medical device manufacturer, located in Chatsworth, California. His studies, at the University of Southern California, included Biomedical Engineering and Business Administration. He will be responsible for driving the company's development, build-up, and marketing programs, as the CEO.

Daniel G. Christopher is a founding partner of the law firm of Guth/Christopher, LLP. He is an equity partner and advisor to PCCA on all matters concerning Business Development, Intellectual Property, Contracting, and Legal.

Prior to co-founding Guth/Christopher in 1997, Mr. Christopher was a partner in the 200 lawyer law firm of Irell & Manella, of Los Angeles, California.

Mr. Christopher received his J.D. from Columbia Law School in 1989, where he was a Harlan Fiske Stone Scholar. Prior to that, he graduated summa cum laude and first in his class from Villanova University. He majored in electrical engineering with an emphasis on digital signal processing, which he continues to draw on, in his counseling of high-tech clients, such as PCCA.

Scott Tichenor is a former CFO and partner of Kemp Brothers Construction, Inc. a large building contractor firm that specializes in large-scale healthcare facility developments. Mr. Tichenor, during his 13-year tenure, was responsible for all fiscal reporting activities. He was a key negotiator on all large-projects and is considered to be a cost accounting and cost controlling expert. He is a CPA with an undergraduate degree in Business Administration from the University of Southern California. He provides construction accounting expertise and management support to PCCA.

Corporate Advisors

A medical and technical advisory panel of world renowned healthcare professionals encompassing numerous specialties and sub-specialties, including integrative medicine, advises PCCA and provides the firm with continuous industry-related feedback.